Costs Associated with Febrile Neutropenia in the US

Abstract

The occurrence of FN in cancer patients receiving chemotherapy results in greater healthcare resource utilization and costs, with FN patients who die accounting for the greatest healthcare costs. Most FN patients experience at least one outpatient FN encounter, and the total cost of treatment for FN continues to be high.

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D

“…A meta-analysis of 14 studies investigating inpatient versus outpatient FN treatment found that the setting of treatment was not significantly associated with treatment failure [55]. According to studies from the US, estimates for inpatient FN management fees range from US $10,143-22,086, while those for outpatient are notably less, ranging from US $985-7830 [56][57][58]. Inpatient treatment still remains the standard setting for FN management according to current European and American guidelines [59,60], but outpatient management for select low-risk patients may be a feasible alternative, with reduced hospitalization costs and risk of healthcare-related infections.…”

Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review

“…The majority of the studies employed a healthcare provider perspective [10,16,[21][22][23]. Four other studies [11,[24][25][26] used a societal perspective. Two studies [11,24] accounted for indirect costs, but used different databases to account for their indirect costs.…”

Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States

“…Previous studies have suggested that febrile neutropenia in breast cancer imposes considerable health care costs (>$12,000), with significant inhospital mortality (3.6 %) and length of stay (8 days) [2]. Furthermore, trend analyses have shown decreasing length of stay (LOS) and mortality rates but rising costs overall in febrile neutropenia-related hospitalizations in the USA [1][2][3]. However, recent data on the national estimates of mortality rate, LOS, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.…”